|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3000 USD | -.--% |
|
-.--% | - |
| 25-10-02 | Joint Disclosure Statement Approved for Irwin Naturals, Inc. | CI |
| 25-09-10 | Reorganization Plan Filed by Irwin Naturals, Inc. | CI |
| Market Cap | 485K 422K 389K 366K 685K 45.69M 690K 4.63M 1.8M 22.51M 1.82M 1.78M 78.04M | P/E 2021 |
105x | P/E 2022 | -0.94x |
|---|---|---|---|---|---|
| Enterprise Value | 21.01M 18.31M 16.88M 15.87M 29.7M 1.98B 29.91M 201M 77.98M 976M 78.87M 77.18M 3.38B | EV / Sales 2021 |
0.13x | EV / Sales 2022 | 0.32x |
| Free-Float |
1.04% | Yield 2021 * |
-
| Yield 2022 | - |
| 3 years | 0.05 |  | 1.5 |
| 5 years | 0.05 | | 4.75 |
| 10 years | 0.05 | | 4.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Klee Irwin
CEO | Chief Executive Officer | 60 | 1993-12-31 |
Mark Green
DFI | Director of Finance/CFO | - | 2024-03-07 |
| Director | Title | Age | Since |
|---|---|---|---|
Klee Irwin
CHM | Chairman | 60 | 1993-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 21-08-15 | Marche | Chief Executive Officer | 1 | - | ||
| 21-08-15 | Marche | Chief Executive Officer | 18,240 | - | ||
| 21-08-15 | Other | Chief Executive Officer | 0 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | -.--% | -80.00% | 721K | |
| -1.21% | -5.37% | +39.94% | +145.38% | 992B | |
| -2.48% | -4.17% | +51.52% | +39.07% | 564B | |
| -2.14% | -3.68% | +16.71% | +56.15% | 391B | |
| -1.18% | +0.25% | +25.86% | +16.53% | 330B | |
| -2.36% | -3.12% | +24.71% | +11.59% | 280B | |
| -2.45% | -2.88% | +24.29% | +30.06% | 279B | |
| -1.91% | -0.87% | -41.95% | -49.25% | 196B | |
| -1.19% | -4.65% | +16.56% | +47.00% | 184B | |
| -1.35% | -1.68% | +14.59% | +56.94% | 156B | |
| Average | -1.63% | +2.85% | +17.22% | +27.35% | 337.12B | |
| Weighted average by Cap. | -1.77% | -2.88% | +28.03% | +63.21% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 100M 87.43M 80.59M 75.81M 142M 9.46B 143M 959M 372M 4.66B 377M 369M 16.15B | 89.47M 77.96M 71.86M 67.59M 126M 8.43B 127M 855M 332M 4.16B 336M 329M 14.4B |
| Net income | 8.62M 7.51M 6.92M 6.51M 12.18M 812M 12.26M 82.32M 31.97M 400M 32.34M 31.64M 1.39B | -3.99M -3.48M -3.21M -3.02M -5.64M -376M -5.68M -38.15M -14.81M -185M -14.98M -14.66M -643M |
| Net Debt | 9.35M 8.15M 7.51M 7.07M 13.22M 881M 13.31M 89.38M 34.71M 434M 35.11M 34.35M 1.51B | 20.53M 17.89M 16.49M 15.51M 29.01M 1.93B 29.22M 196M 76.18M 953M 77.05M 75.4M 3.3B |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- IWIN Stock
Select your edition
All financial news and data tailored to specific country editions
